Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy...
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known...
MD Anderson Research Highlights: ASH 2022 Special Edition
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations by MD Anderson researchers at the 2022 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches and novel...
MD Anderson Research Highlights: SABCS 2022 Special Edition
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...
Some breast cancer patients with high responses to chemotherapy may not need surgery
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery...
MD Anderson and WHO establish new international collaboration to reduce women’s cancers
The University of Texas MD Anderson Cancer Center and World Health Organization (WHO) today announced a formal agreement to establish a new...
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...
Preoperative combination chemotherapy improved survival in patients with pancreatic cancer
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased...
MD Anderson Research Highlights: EHA 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being...
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
ABSTRACT LBA7502
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free...
TJ Gan, M.D., to join MD Anderson as Division Head of Anesthesiology, Critical Care and Pain Medicine
The University of Texas MD Anderson Cancer Center today announced that Tong Joo (TJ) Gan, M.D., has been named Division Head of Anesthesiology...
NK cells combined with bispecific antibody showed strong response for patients with lymphoma
Abstract: CT003
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from...
Lee Ellis honored by AACR for contributions to education and training in cancer research
The American Association for Cancer Research (AACR) has honored Lee Ellis, M.D., professor of Colon and Rectal Surgery at The University of...
Karen Lu honored by AACR for contributions to cancer research
The American Association for Cancer Research (AACR) has honored acclaimed investigator Karen Lu, M.D., chair of Gynecologic Oncology and Reproductive...
Axi-cel proves effective as first-line treatment for high-risk lymphoma
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with...
Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option
Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes...